A prospective open-label study of home use of mifepristone for medical abortion in Nepal.

Objective: To assess the uptake and acceptability of self-administration of mifepristone at home for medical abortion in Nepal.

Methods: A prospective, comparative, non-randomized, open-label study was conducted at two hospitals in Kathmandu, Nepal, between November 11, 2009, and January 15, 2011. All women in good health and aged 18 years or older who sought medical abortion after fewer than 64 days of pregnancy were enrolled.

Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam.

Objective: To assess the potential advantages of combined mifepristone-misoprostol versus misoprostol-only for early medical abortion.

Methods: A double-blind randomized placebo controlled study was conducted that enrolled 441 pregnant women (<63 days since last menstrual period) at 2 hospitals in Tunisia and Vietnam. The mifepristone-misoprostol group (n=220) received 200mg of mifepristone on day 1 and 800 μg buccal misoprostol followed by placebo 3 hours later on day 2.